

Table 2. Statistical analysis of the protein levels in the hippocampus of male and female WT and APP/PS1 mice chronically treated with THC+CBD or vehicle.

	Glutamate transporters		Glutamate receptors			Glutamate signaling					
	GLT-1	EAAT3	GLUA1	GluN1	mGlu ₅	Fyn	pFyn	pFyn/Fyn	eEF2	peEF2	peEF2/eEF2
Two-way ANOVA											
Genotype	<i>N.S.</i>	<i>N.S.</i>	<i>N.S.</i>	<i>N.S.</i>	<i>N.S.</i>	F (1, 22) = 6.880, p<0.05	F (1, 21) = 5.199, p<0.05	<i>N.S.</i>	F (1, 21) = 8.338, p<0.01	F (1, 21) = 3.602 P=0.0715	<i>N.S.</i>
Treatment	<i>N.S.</i>	F (1, 19) = 5.968, p<0.05	<i>N.S.</i>	<i>N.S.</i>	F (1, 19) = 5.413, p<0.05	<i>N.S.</i>	<i>N.S.</i>	<i>N.S.</i>	<i>N.S.</i>	F (1, 21) = 3.279 P=0.0845	F (1, 21) = 6.169, p<0.05
Genotype x Treatment	<i>N.S.</i>	<i>N.S.</i>	<i>N.S.</i>	<i>N.S.</i>	<i>N.S.</i>	<i>N.S.</i>	<i>N.S.</i>	<i>N.S.</i>	<i>N.S.</i>	<i>N.S.</i>	<i>N.S.</i>
Tukey's <i>post hoc</i> test											
WT vs APP/PS1											
Vehicle	<i>N.S.</i>	<i>N.S.</i>	<i>N.S.</i>	<i>N.S.</i>	<i>N.S.</i>	<i>N.S.</i>	<i>N.S.</i>	<i>N.S.</i>	<i>N.S.</i>	<i>N.S.</i>	<i>N.S.</i>
THC+CBD	<i>N.S.</i>	<i>N.S.</i>	<i>N.S.</i>	<i>N.S.</i>	<i>N.S.</i>	p<0.05	<i>N.S.</i>	<i>N.S.</i>	p<0.01	<i>N.S.</i>	<i>N.S.</i>
Vehicle vs THC+CBD											
WT	<i>N.S.</i>	<i>N.S.</i>	<i>N.S.</i>	<i>N.S.</i>	<i>N.S.</i>	<i>N.S.</i>	<i>N.S.</i>	<i>N.S.</i>	<i>N.S.</i>	<i>N.S.</i>	p<0.05
APP/PS1	<i>N.S.</i>	<i>N.S.</i>	<i>N.S.</i>	<i>N.S.</i>	<i>N.S.</i>	<i>N.S.</i>	<i>N.S.</i>	<i>N.S.</i>	<i>N.S.</i>	<i>N.S.</i>	<i>N.S.</i>

Two-way ANOVA with genotype and treatment as between-subjects factors was applied for the analysis of protein levels. When one factor or interaction between factors were significant, comparisons between groups were performed by Tukey's *post hoc* test. *N.S.*, not significant difference. See Materials and methods for details.